Universitaet Muenster
12
7
8
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
25%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury
Role: lead
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Role: lead
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Role: lead
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Role: lead
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
Role: lead
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Role: lead
tTF-NGR Randomized Study - STS
Role: lead
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Role: lead
Long-term follow-up of patients treated with GD2IL18CART
Role: lead
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)
Role: lead
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Role: lead
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Role: lead
All 12 trials loaded